Company Press Releases 5.6.13CytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb® With L.IN.C. Medical Systems in the United Kingdom and Ireland 5.1.13CytoSorbents Provides Exclusive Interview with medGadget 4.15.13CytoSorbents Appoints Christopher Cramer as Vice President of Business Development 4.11.13CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract 4.8.13CytoSorbents Announces Trauma Advisory Board 4.3.13CytoSorbents Provides Corporate Update and Reports 2012 Year End Financial Results 3.26.13CytoSorbents Provides Update on ISICEM 2013 Critical Care Conference 3.13.13CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference 3.5.13CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital Forum on March 8, 2013 2.8.13CytoSorbents Appoints Ronald Berger as Interim Chief Financial Officer 1.29.13CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers 1.9.13CytoSorbents 2012 End of Year Shareholder Letter 1.4.13CytoSorbents to Present at the OneMedForum 2013 Finance Conference 11.30.12CytoSorbents Appoints Thomas Bocchino as Chief Financial Officer 11.26.12CytoSorbents Clarifies Q3 2012 Earnings Press Release 11.21.12CytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results 11.16.12CytoSorbents Corporation Filing of 10-Q Delayed Due to Superstorm Sandy 9.27.12CytoSorbents Continues to Expand Market Awareness of Its Technologies 9.24.12US Army Grants CytoSorbents $1 Million Phase II SBIR Trauma and Burn Injury Award 9.7.12CytoSorbents Sponsors the German Sepsis Society and Sepsis Heroes in Honor of World Sepsis Day 9.5.12CytoSorbents To Present at Rodman & Renshaw 2012 Global Investment Conference 8.13.12CytoSorbents Reports Corporate Update and Second Quarter 2012 Financial Results 8.9.12CytoSorbents to Present and Exhibit at the Military Health System Research Symposium 8.6.12DARPA Awards $3.8 Million Contract to CytoSorbents Corporation 7.25.12Brean Murray Initiates Coverage with "Buy" Rating 6.29.12Improvement in Heart Function in Organ Donor Animal Model Using CytoSorb® Highlighted at the Western Thoracic Surgical Association Meeting 6.20.12CytoSorbents Appoints Dr. Christian Steiner as VP of Sales and Marketing and Hires Core Sales Force That Marks the Official Launch of CytoSorb® in Germany 6.20.12CytoSorbents Announces Departure of CFO David Lamadrid 6.14.12CytoSorbents to Present at the Marcum MicroCap Conference 6.5.12Zacks Small Cap Research Initiates CytoSorbents with Outperform Rating 5.20.12CytoSorbents Publishes Responses to Frequently Asked Questions - May 2012 5.15.12CytoSorbents Reports Corporate Update and First Quarter 2012 Financial Results 5.11.12Dr. Phillip Chan Named Finalist for Ernst & Young Entrepreneur of the Year® 2012 Award in New Jersey 5.08.12CytoSorbents to Present at Frankfurt MedTech Investor Forum 4.19.12CytoSorbents Receives European Trademark for CytoSorb® 4.09.12CytoSorbents Corporation Establishes European Subsidiary 3.31.12CytoSorbents Corporation Reports Full Year 2011 Financial Results and Corporate Update 3.07.12CytoSorbents to Exhibit and Host Research Symposium at Major International Critical Care Conference 2.13.12CytoSorbents Strengthens Balance Sheet Through Convertible Note 2.07.12CytoSorbents to Exhibit at the 2012 Symposium of Intensive Medicine and Intensive Care 1.11.12CytoSorbents 2011 End of Year Shareholder Letter 12.14.11CytoSorbents Awarded US Army SBIR Trauma Grant 12.09.11CytoSorbents Announces Purchase Agreement for up to $8.5 Million With Lincoln Park Capital 11.15.11CytoSorbents Corporation Reports Third Quarter 2011 Financial Results and Corporate Update 10.25.11CytoSorbents Corporation to Present at the IN3 Medical Device Summit 10.17.11CytoSorbents Corporation Launches HemoDefend Purification Technology Platform for Blood Transfusion Applications at the AABB Conference CTTXPO Exhibition 9.23.11CytoSorbents Corporation to Exhibit at the European Society of Intensive Care Medicine Congress in Berlin and at the AdvaMed Conference in Washington D.C. 9.13.11CytoSorbents Announces New Statistical Analysis and Confirms Statistical Significance in 28-Day Mortality 9.8.11CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference 9.7.11CytoSorbents Corporation Announces Additional Data From European Sepsis Trial 9.1.11CytoSorbents Corporation to Exhibit at the German Sepsis Society International Congress 8.16.11CytoSorbents Corporation Reports Second Quarter 2011 Financial Results 8.4.11CytoSorbents Corporation to Exhibit at the Advanced Technology Applications for Combat Casualty Care Conference 6.6.11CytoSorbents Corporation Releases Shareholder Letter 3.31.11CytoSorbents Corporation Achieves European Union Regulatory Approval for CytoSorb™ 2.22.11CytoSorbents Closes Convertible Note With Additional $1.25 Million Raised 02.17.11CytoSorbents Corporation Broadens Its Intellectual Property Portfolio 12.30.10CytoSorbents Corporation to Present at the OneMedForum 2011 Finance Conference 11.17.10CytoSorbents Corporation Reports Third Quarter 2010 Financial Results 11.2.10CytoSorbents Corporation Awarded $488,958 Grant from the Federal Qualifying Therapeutic Discovery Project Program 09.27.10CytoSorbents Corporation Achieves ISO 13485 Certification 09.09.10CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference 09.01.10CytoSorbents' Chief Financial Officer is named a finalist for '2010 CFO of the Year' award by NJBIZ 08.19.10CytoSorbents Corporation Reports Second Quarter 2010 Financial Results 08.11.10CytoSorbents Corporation to Present Today at the Emerging Medical Technologies Spotlight Online Conference 07.26.10CytoSorbents Corporation to Exhibit at the Force Health Protection Conference and ATACCC 06.08.10CytoSorbents Corporation to Present at the In3 East Medical Device Conference 05.24.10CytoSorbents Corporation to Present at BioNJ BioPartnering Conference 05.17.10CytoSorbents Corporation Reports First Quarter 2010 Financial Results 05.10.10Cytosorbents Corporation Enters Into Funding Agreement 05.06.10 MedaSorb Technologies Announces Company Name Change to CytoSorbents Corporation 04.12.10 MedaSorb Technologies Corporation Reports Full Year 2009 Financial Results 02.17.10 MedaSorb Technologies Corporation Improves Cash Position and Hits Midway Point in Study Enrollment 01.11.10MedaSorb Technologies Corporation to Present at the Biotech Showcase™ 2010 11.13.09MedaSorb Technologies Corporation Provides Clinical Update 11.13.09MedaSorb Technologies Corporation Announces Q3 2009 Results and Files Form 10-Q, Quarterly Report 8.18.09MedaSorb Technologies Corporation to Present at the Rodman & Renshaw Global Investment Conference 7.16.09MedaSorb and CytoSorbents CEO Featured in Interviews by The Wall Street Transcript and CEO-CFO Interviews 5.06.09 CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak 3.30.09 CytoSorbents, Inc. Recognized as "Company Most Likely to Succeed" at the 2009 New Jersey Venture Conference and Provides Clinical Update 2.03.09 MedaSorb Technologies Corporation Improves Balance Sheet 1.9.09 MedaSorb Technologies Corporation Announces Management Changes August 2008 Letter To Our Shareholders 1.4.07 MedaSorb Announces IDE Filing with the FDA 11.3.06 MedaSorb Technologies Corporation Files New Patent Application 10.27.06 MedaSorb Technologies Adds Strategic Technology Patent 9.19.06 MedaSorb Announces That They Intend to File Investigational Device Exemption With the FDA 8.7.06 MedaSorb Technologies to Begin Trading under the Symbol MSBT 7.25.06 Gilder Enterprises, Inc. Acquires MedaSorb Corporation and Raises $5.25 Million
Publications